L-Arginine in Children Having Sickle Cell Disease With Increased Tricuspid Regurgitant Jet Velocity

• Status: Recruiting
• Trial end date: 2024-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to investigate the possible efficacy and safety of L-Arginine in children having Sickle Cell Disease with increased Tricuspid Regurgitant Jet Velocity

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University

Criteria

Inclusion Criteria:

• children having Sickle Cell Disease with increased Tricuspid Regurgitant Jet Velocity

• age 5-18 years

Exclusion Criteria:

• Another chronic hemolytic anemia.

• Patients with documented causes of pulmonary hypertension other than SCD.

• Allergy to L-arginine.

• Patients with Asthma.

• Hepatic dysfunction: serum Alanine Aminotransferase (ALT) > 3X upper value.

• Renal dysfunction: Creatinine level greater than or equal to 1.2 mg/dl.